Converge Bio Raises $25 Million to Scale Generative AI Systems for Every Biotech Firm

Converge Bio announced a $25 million Series A funding round today to expand its efforts in bringing generative AI to the entire pharmaceutical industry. Led by Bessemer Venture Partners, the round included participation from TLV Partners, Vintage Investment Partners, and Saras Capital. Technical leaders from Meta, OpenAI, and Wiz also joined the round, highlighting a significant crossover between enterprise AI expertise and life sciences. This brings the total capital raised to $30 million just eighteen months after the company's inception.

Transforming Biological Data into Medicine

The Boston-based startup differentiates its approach by focusing on end-to-end systems rather than isolated models. CEO Dov Gertz noted that biologists often face a significant gap between high-performing AI benchmarks and the actionable results required in a laboratory setting. Converge's platform allows scientists to identify novel drug targets and optimize antibody designs without needing to write code. The system is designed to plug directly into existing development workflows to replace slow trial and error methods. Commercial results have already proven significant across more than 40 completed programs over the last year. Partners using the platform reported improving protein manufacturing yields by four to seven times, which is a critical factor for the financial viability of new medicines. The technology is currently being applied to challenges in oncology, neurodegenerative diseases, and autoimmune disorders. With over a dozen active pharma customers, the company is moving quickly to industrialize biological data at scale.

Strategic Backing and Industry Momentum

Investors are drawn to the company's ability to turn biological data into a functional language for drug development. By treating DNA and proteins as structured information, the platform creates a tight feedback loop between digital predictions and physical validation. Andrew Hedin of Bessemer Venture Partners described the company as a results-driven player positioned to become the leading generative AI lab for the life sciences. This approach moves the industry beyond theoretical promise toward measurable scientific outcomes. The funding arrives during a period of intense momentum for the sector, following the Nobel Prize for AlphaFold and the rise of Eli Lilly as a trillion-dollar giant. Recent major partnerships, such as the one between Eli Lilly and Nvidia to build the industry's largest supercomputer, highlight the shifting priorities of the global market. Converge Bio aims to democratize these advanced capabilities for companies that lack the internal resources of the world's largest pharmaceutical firms.

Democratizing Advanced Computational Tools

Looking ahead, the company plans to make every biotech firm an AI company by providing validated tools that integrate with wet-lab experiments. The platform allows customers to create private, fine-tuned instances of models using their own data while maintaining full ownership of the results. This focus on privacy and accessibility is intended to speed up the discovery of treatments for a wide range of complex diseases. The combination of domain expertise in bioinformatics and enterprise-grade machine learning engineering positions the team to bridge the remaining gap between code and cure.